This phase I trial is evaluating the safety and dose of an investigational immunotherapy drug (AMG 160) in patients with metastatic castration resistant prostate cancer.
This trial is treating patients with castration resistant prostate cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer
This is a sequentially assigned, dose escalation and expansion study, in which eligible patients will receive AMG 160 intravenously at different dose levels.
Recruiting Hospitals Read More